CDC37 and neoplasm: The inhibition of HSP90 or CDC37 alone (by RNA interference or by small molecule inhibitors of HSP90) has shown encouraging anti-tumor effects in cell-based studies of multiple tumors, which are associated with enhanced degradation and decreased phosphorylation of oncogenic HSP90/CDC37 client protein kinases [11, 16, 17, 33].